# Acadia Healthcare Company, Inc. (ACHC) — Financial Analysis

**Exchange:** Nasdaq  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-03  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ACHC/thesis · /stocks/ACHC/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: ACHC
step: "04"
title: Financial Quality & Adversarial Sweep
created: 2026-06-03
---

### Step 04 — Financial Quality & Adversarial Sweep: ACHC

#### [S1] Statement Quality Assessment

##### Adjustments Required for Comparability

ACHC's GAAP financials require several adjustments for clean trend analysis [S1]:

| Item | Period | GAAP Impact | Adjustment | Adjusted Metric |
|------|--------|-------------|-----------|----------------|
| Desert Hills Litigation settlement | FY2023 | ($394.2M) pre-tax charge | Add back | Adj. EBITDA FY2023 ~$567M |
| Desert Hills cash payments | FY2024 OCF | (~$300M) outflow | Normalize OCF | Adj. OCF FY2024 ~$430M |
| UK operations disposal | FY2021 | $1.0B+ gain on sale | Exclude | FY2021 financials are US-only post-sale |
| Goodwill impairment | FY2025 (Q4) | (~$1.5B) non-cash | Add back | Adj. EBITDA FY2025 $608.9M (as reported adj.) |
| Goodwill impairment | FY2020 | (~$672M) net loss | Exclude | Pre-operational distortion |
| Transaction/legal/other | FY2023-FY2024 | $46-62M annual | Partial add-back | Portion is recurring (legal reserves) |

**Clean adjusted metrics (FY2022-FY2025):**

| Metric | FY2022 | FY2023 Adj. | FY2024 Adj. | FY2025 Adj. |
|--------|--------|-------------|-------------|-------------|
| Revenue | $2,610M | $2,929M | $3,154M | $3,313M |
| Adj. EBITDA | ~$540M | ~$567M | ~$608-671M | $608.9M |
| Adj. EBITDA Margin | ~20.7% | ~19.4% | ~19.3-21.3% | ~18.4% |
| Adj. OCF | ~$381M | ~$462M | ~$430M* | ~$132M** |

*FY2024 adj. OCF = reported $130M + ~$300M Desert Hills payments restored
**FY2025 OCF of $132M appears to be without major one-time items; CapEx was $572M

Sources: [S1] XBRL data; 10-K FY2024 MD&A; StockAnalysis; consensus

##### Revenue Recognition Quality

- Revenue recognized on an accrual basis as services delivered; per-diem and fee-for-service models are straightforward
- Contractual allowances: ACHC books gross charges then nets against expected payor reimbursement. The net realization is what's reported. No known channel stuffing or revenue manipulation concerns.
- Accounts receivable DSO of 43 days (FY2024) is reasonable for a diversified government + commercial payor mix. Slight improvement from 45 days in FY2023. No significant DSO deterioration trend.

Sources: [S1] 10-K FY2024 revenue recognition accounting policy; MD&A

#### [S2] Balance Sheet Quality

##### Goodwill & Intangibles

| Item | FY2022 | FY2023 | FY2024 | FY2025 |
|------|--------|--------|--------|--------|
| Total Assets | $4,988M | $5,359M | $5,957M | $5,527M |
| Net PP&E | $2,087M | $2,384M | $2,972M | $3,245M |
| Goodwill + Intangibles (est.) | $2,000M+ | $2,000M+ | $2,000M+ | ~$500M* |

*FY2025 goodwill significantly reduced after $1.5B impairment.

**Goodwill impairment in FY2025** confirms that prior M&A (2012-2019 acquisition phase) was done at prices that did not generate adequate returns at current earnings levels. This is a red flag for prior capital allocation discipline but does not directly impair future operations.

Post-impairment goodwill balance is more defensible at current EBITDA levels.

Sources: [S2] StockAnalysis balance sheet; 10-K FY2024/FY2025

##### Debt Structure & Leverage

| Metric | FY2022 | FY2023 | FY2024 | FY2025 | Q1 2026 |
|--------|--------|--------|--------|--------|---------|
| Total Debt ($M) | 1,529 | 1,499 | 2,084 | 2,643 | 2,669 |
| Net Debt ($M) | 1,431 | 1,399 | 2,008 | 2,510 | 2,510 |
| Adj. EBITDA ($M) | ~540 | ~567 | ~608 | ~609 | — |
| Net Leverage (x) | 2.6x | 2.5x | 3.3x | 4.1x | ~4.1x |

**FY2026 leverage target:** 3.9-4.2x per company guidance — implies minimal deleveraging even at $593M EBITDA midpoint. Debt service of ~$200M+/year (interest + amortization) is manageable but leaves limited FCF headroom.

**Credit facility:** Post-2025 refinancing (prior March 2026 maturity resolved). Specific new terms not confirmed in cached data, but company disclosed refinancing in 2025 filings.

Sources: [S2] StockAnalysis balance sheet; XBRL; consensus

#### [S3] Cash Flow Quality

**Operating Cash Flow normalization:**

| Year | GAAP OCF | Key Adjustments | Normalized OCF | CapEx | Normalized FCF |
|------|----------|----------------|---------------|-------|---------------|
| FY2022 | $381M | None material | $381M | $296M | $85M |
| FY2023 | $462M | Settlement booked not paid | ~$462M | $424M | $38M |
| FY2024 | $130M | +$300M Desert Hills pmts | ~$430M | $690M | (~$260M) |
| FY2025 | $132M | None material | $132M | $572M | ($440M) |

**True normalized FCF burn FY2024-2025:** ~($260M) to ($440M)/year during peak expansion.

**Maintenance CapEx:** ~$104M/year (FY2024 disclosure); ~3.3% of revenue. Economically, expansion CapEx is voluntary (growth investment), not required to maintain the base business. This is an important distinction for FCF-based valuation — ACHC's base business generates substantial OCF; the FCF burn is a growth reinvestment choice.

**FCF recovery path:** Management guidance calls for FCF positive by end-2026. CapEx guidance $450-570M for FY2026 vs. $572M in FY2025. If adj. EBITDA holds at $590M and CapEx declines to $450M, the math requires D&A-adjusted OCF of ~$600M+ to get to positive FCF. This requires: (a) no additional working capital drag and (b) no further settlement payments.

Sources: [S3] XBRL cash flow; 10-K FY2024 MD&A; investor presentation 2024; consensus

#### [S4] Adversarial Research Sweep

*Note: Transcript analysis was not performed; adversarial research conducted via SEC disclosure review, press release analysis, and web search for third-party investigations and short seller research.*

**Finding 1: DOJ Civil Investigation (Material)**
- Acadia disclosed a DOJ Civil Division investigation focused on billing practices at certain substance use disorder (SUD) treatment facilities (CTCs / opioid treatment programs)
- Investigation is civil, not criminal (as of most recent disclosure); subpoenas issued
- Magnitude of potential settlement: unquantified in filings; precedent cases (Sheppard Pratt: $15M; large behavioral chains: $50-300M range)
- **Risk assessment:** Real and material; creates uncertainty on balance sheet and M&A optionality. The DOJ investigation also likely explains the absence of insider open-market buying during the 70-85% stock drawdown.
- Source: 8-K disclosures; risk factor in 10-K FY2024

**Finding 2: Desert Hills Litigation (Resolved Financially, Ongoing Reputationally)**
- Desert Hills Recovery Center (Arizona facility) was involved in patient safety incidents and insurance fraud allegations (billing for services not rendered, patient welfare violations)
- $394.2M settlement (FY2023 charge; cash paid in FY2024)
- Desert Hills was operated under ACHC management; this is a quality-of-care and billing compliance red flag
- Post-settlement, ACHC implemented compliance program enhancements
- Source: 10-K FY2023/FY2024; press reporting

**Finding 3: Goodwill Impairment ($1.5B, FY2025)**
- Non-cash; does not affect operations or liquidity directly
- However, it confirms prior acquisitions were executed at prices not justified by subsequent earnings power
- Raises questions about ROIC discipline in the acquisition phase (2012-2019)
- Management response: pivot away from acquisitions toward de novo + JV growth (lower purchase-price risk)
- Source: StockAnalysis; consensus data (Q4 FY2025 results)

**Finding 4: High Short Interest (24.9% of Float)**
- 22.6M shares short (8.2 days to cover) suggests significant bearish conviction from professional investors
- Short thesis likely focuses on: DOJ settlement risk, Medicaid rate pressure, leverage trajectory, FCF negativity
- Short interest peaked ~35.9% in February 2026 and has moderated (stock up from $11.43 low to $24.42)
- Source: StockAnalysis ownership data; consensus

**Finding 5: Labor Inflation / Staffing Challenges**
- Behavioral health clinician shortage is acute; travel nurses and contract staff inflate SWB costs
- SWB at 53.6% of revenue is high; no meaningful improvement in this ratio FY2022-FY2024
- Source: 10-K FY2024 risk factors; industry analysis

**Finding 6: CEO Transition**
- Christopher Osteen installed as CEO (2025/2026) replacing prior CEO; significant management change during critical execution phase
- New CEO background (Kindred Healthcare) is relevant (post-acute/behavioral); not an external hire without sector experience
- Source: Proxy; press research; investor presentation

**Finding 7: No Known Short-Seller Reports**
- No high-profile short-seller reports (Muddy Waters, Hindenburg, etc.) targeting ACHC found in research
- The DOJ investigation and Desert Hills are known to the market and already partially priced in

**Overall Adversarial Assessment:**
The bear case has merit on DOJ risk, leverage, and payor pressure — but the Desert Hills issue is largely resolved financially, the goodwill impairment is non-cash, and the DOJ investigation appears civil in scope. The fundamental revenue stream (behavioral health inpatient) is structurally sound. The primary financial risk is FCF negativity persisting beyond 2026 if CapEx does not normalize or if EBITDA disappoints.

Sources: [S4] 10-K FY2024 risk factors; 8-K disclosures; StockAnalysis; web research

#### Source Index
| ID | Source | Date |
|----|--------|------|
| S1 | XBRL data; 10-K FY2024 MD&A; StockAnalysis; consensus | 2026-06-03 |
| S2 | StockAnalysis balance sheet; XBRL; consensus | 2026-06-03 |
| S3 | XBRL cash flow; 10-K FY2024 MD&A; investor presentation; consensus | 2026-06-03 |
| S4 | 10-K FY2024 risk factors; 8-K disclosures; StockAnalysis; web research | 2026-06-03 |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ACHC/fundamental

## Navigation

- Overview: /stocks/ACHC
- Financials (this page): /stocks/ACHC/financials
- Thesis: /stocks/ACHC/thesis
- Investment Memo: /stocks/ACHC/memo
- Coverage universe: /stocks